PFC "Renewal" has launched a new production complex in the Novosibirsk region with a capacity of 100 million packages per year.
Russian pharmaceutical company PFC "Renewal" (Renewal brand) officially launched a new large-scale production complex for the production of vital medicines in the Novosibirsk region. ""The presentation of the investment project took place on the sidelines of the International Forum of Technological Development Technoprom-2026 within the framework of the meeting of the Coordinating Council of the Interregional Association "Siberian Agreement" (AMIS) with the participation of representatives of the Ministry of Industry and Trade of Russia.
The new project is included in the unified register of priority industrial and technological projects of the Siberian Federal District, which are at the stage of high investment readiness.
The area of the new production building is more than 18.1 thousand square meters, and the design capacity of the workshop is 100 million packages of finished products per year. Production at the new site is organized according to the full cycle — from the receipt of raw materials to the release and packaging of finished medicinal products.
The new facilities are aimed at closing the deficit in critically important segments of Russian healthcare. The site has launched the production of two key groups of medicines:
- Sterile preparations (VED): hormonal injectable drugs (Dexamethasone, Prednisone), infusion solutions (sodium chloride, Ringer's solution, glucose), as well as a line of eye drops (Taurine, Timolol, Pilocarpine, Sodium Sulfacyl, Levomycetin, Ciprofloxacin);
- Solid dosage forms: The site is focused on import substitution of demanded foreign medicines — effervescent tablets of paracetamol and acetylsalicylic acid, as well as cardiological drugs Rivaroxaban and Candesartan.
The launch of high-tech lines will create more than 200 new jobs in the region. Currently, the facility has been commissioned, and commissioning is actively underway: the workshop will be prepared for licensing in stages, with the first stage scheduled for the period from the fourth quarter of 2026 to the second quarter of 2027 inclusive.
"Renewal" PFK signed a strategic partnership agreement with during the "Technoprom-2026" forumNovosibirsk State University (NSU). The cooperation provides for joint research and development (R&D), technology transfer and accelerated commercialization of developments, including the creation of new analytical methods for detecting impurities in drugs at the registration stage.
Today, Renewal (which has been operating on the market since 2002) has two large production sites in the Novosibirsk region — in Novosibirsk and the Suzun work settlement. The company demonstrates stable financial growth: by the end of 2025, the company's revenue reached 21.1 billion rubles, and the total sales volume amounted to 188 million packages of medicines.
"Production will be organized in a full cycle — from the receipt of raw materials to the output of finished products. More than 200 new jobs will be created to ensure all stages of production," the company's press service noted.
Source: ФАРМПРОМ
